.

ISSN 2063-5346
For urgent queries please contact : +918130348310

FORMULATION DEVELOPMENT AND PHARMACOLOGICAL EVALUATION OF POLYHERBAL FORMULATIONS FOR THE TREATMENT OF OVARIAN CANCER

Main Article Content

Mohammad Khalid, Snehal Nursing Pawar, Sonal Nikunj Solanki, Vishakha R.Shelke, Madhura Satish Chothave, Asha Sambhaji Jadhav, Choda Pradeep Kumar, Kavita Yogesh Pawar
» doi: 10.48047/ecb/2023.12.si6.374

Abstract

An endocrine disorder called PCOS causes larger ovaries with little cysts on the borders. The purpose of the current investigation is to determine whether a polyherbal formulation can treat female Albino Wistar rats with PCOS that have been brought on by letrozole. Keeping OECD rule 423, a solitary portion (2000 mg/kg) of the polyherbal plan was managed to female Pale skinned person Wistar rodents (20 weeks, 250 g) for an intense poisonousness examination. Six gatherings of six female Pale skinned person Wistar rodents were utilized in the PCOS-actuated examination. Group I received a daily vehicle control of a 0.5% carboxymethylcellulose (CMC) suspension. In order to induce PCOS, women in Groups II–VI were given oral letrozole (1 mg/kg) for 21 days. Collection III: 1 mg/kg clomiphene citrate; Collection IV: 500 mg/kg; Collection V: 750 mg/kg; Collection VI: 1000 mg/kg were given to the animal up to 50 days following PCOS administration. The eighth most common type of deadly cancer of the reproductive system is ovarian cancer. After menopause, it affects the ovary and results in aberrant cell development. Every year, more than one million cases are treated or diagnosed throughout the world.

Article Details